<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042245</url>
  </required_header>
  <id_info>
    <org_study_id>XH-19-005</org_study_id>
    <nct_id>NCT05042245</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules</brief_title>
  <official_title>The Efficacy and Safety of Ornithine Aspartic Acid Granules in Non-Alcoholic Fatty Liver Disease Against Silymarin Capsules: a Randomized, Double-Blind, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, double-dummy, and positive control clinic&#xD;
      trial which explores the efficacy and safety of ornithine aspartate granules in the treatment&#xD;
      of non-alcoholic fatty liver disease against silymarin capsules. The hypothesis is that the&#xD;
      ornithine aspartate granules have similar or better efficacy than the silymarin capsules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients whose controlled attenuation parameter (CAP) value returned to normal or changed by more than 10%</measure>
    <time_frame>Assessed at 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changed degree of quality-of-life measured by the Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH</measure>
    <time_frame>Assessed at 4 weeks, 12 weeks, and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients whose alanine aminotransferase (ALT) level returned to normal or changed by more than 50%</measure>
    <time_frame>Assessed at 4 weeks, 12 weeks, and 24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The changed amount of blood ammonia</measure>
    <time_frame>Assessed at 4 weeks, 12 weeks, and 24 weeks</time_frame>
    <description>An exploratory indicator</description>
  </other_outcome>
  <other_outcome>
    <measure>The changed amount of body fat</measure>
    <time_frame>Assessed at 4 weeks, 12 weeks, and 24 weeks</time_frame>
    <description>An exploratory indicator of body composition analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>The changed amount of body fat proportion</measure>
    <time_frame>Assessed at 4 weeks, 12 weeks, and 24 weeks</time_frame>
    <description>An exploratory indicator of body composition analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>The changed amount of muscle mass</measure>
    <time_frame>Assessed at 4 weeks, 12 weeks, and 24 weeks</time_frame>
    <description>An exploratory indicator of body composition analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>ornithine aspartate granule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be given aspartate ornithine granules (3 g po tid, after three meals) and silymarin capsule simulant (140 mg po bid, before breakfast and dinner).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>silymarin capsule group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be given silymarin capsule (140 mg po bid, before breakfast and dinner) and aspartate ornithine granules simulant (3 g po tid, after three meals) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ornithine aspartate granule</intervention_name>
    <description>Ornithine aspartate granules in the experimental arm.</description>
    <arm_group_label>ornithine aspartate granule group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin capsule</intervention_name>
    <description>Silymarin capsules in the active comparator arm.</description>
    <arm_group_label>silymarin capsule group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin capsule simulant</intervention_name>
    <description>Silymarin capsule simulant in the experimental arm.</description>
    <arm_group_label>ornithine aspartate granule group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ornithine aspartate granule simulant</intervention_name>
    <description>Ornithine aspartate granule simulant in the active comparator arm.</description>
    <arm_group_label>silymarin capsule group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Consistent with NAFLD diagnosis criteria, and during previous one month, the B-mode&#xD;
             ultrasonography showed diffuse fatty liver and Fibroscan test showed that CAP value &gt;&#xD;
             248 db/m;&#xD;
&#xD;
          -  2. During previous one month, serum ALT level was higher than 1.5 times the upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  3. BMI is not more than 30 kg/m2.&#xD;
&#xD;
          -  4. Voluntary to participate in the research and signed a written informed consent to&#xD;
             comply with the trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Hereditary metabolic or autoimmune liver disease, hepatotropic and non-hepatotropic&#xD;
             virus infection, drug/toxic/alcoholic/biliary liver injury, or any end-stage liver&#xD;
             disease; fatty liver disease caused by one of the following reasons: total parenteral&#xD;
             nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome,&#xD;
             beta-lipoprotein deficiency and some insulin resistance (IR) related syndromes (lipid&#xD;
             atrophic diabetes, Mauriac syndrome);&#xD;
&#xD;
          -  2. Hepatic or extrahepatic malignant tumors;&#xD;
&#xD;
          -  3. Severe heart failure or renal failure (serum creatinine &gt; 3mg/100mL);&#xD;
&#xD;
          -  4. Allergic constitution, or allergic to amino acid drugs or to ornithine aspartate&#xD;
             and its constituents or to silymarin;&#xD;
&#xD;
          -  5. ALT or γ-glutamyl transpeptidase (γ-GT) are greater than 5 times the upper limit of&#xD;
             normal, or total bilirubin (TBIL) &gt; 51 umol/L.;&#xD;
&#xD;
          -  6. Confirmed liver cirrhosis or Fibroscan test showed E value &gt; 12.5 kilopascal (KPa);&#xD;
&#xD;
          -  7. Triglyceride &gt; 5.6mmol/L;&#xD;
&#xD;
          -  8. Diabetes diagnosed for more than 5 years, combined with current insulin therapy or&#xD;
             taking hypoglycemic drugs with poorly controlled condition (HbA1c &gt; 9%).&#xD;
&#xD;
          -  9. Women who are pregnant, nursing or preparing for pregnancy;&#xD;
&#xD;
          -  10. Suspected or confirmed excessive drinking (equivalent alcohol amount: male, &gt;&#xD;
             40g/d; female, &gt; 20g/d), or history of drug abuse;&#xD;
&#xD;
          -  11. Combined use of drugs with liver protection and anti-inflammatory effects, as well&#xD;
             as any Chinese patent medicine, Chinese herbal medicine, or health products that may&#xD;
             have liver protection or liver damage effects;&#xD;
&#xD;
          -  12. Taking weight-loss drugs or receiving weight-loss treatment;&#xD;
&#xD;
          -  13. Situations of inappropriate participation judged by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian G Fan, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian G Fan, PHD</last_name>
    <email>fattyliver2004@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian G Fan, PHD</last_name>
      <email>fattyliver2004@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiangao Fan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

